These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16110693)

  • 21. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron.
    Jones S; Strobl R; Crosby D; Burkard JF; Maye J; Pellegrini JE
    AANA J; 2006 Apr; 74(2):127-32. PubMed ID: 16617916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INM investigations into drugs for seasickness prophylaxis.
    Pingree BJ
    J R Nav Med Serv; 1994; 80(2):76-80. PubMed ID: 7707278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual side-effects from transdermal scopolamine (hyoscine).
    Firth AY; Walker K
    Dev Med Child Neurol; 2006 Feb; 48(2):137-8. PubMed ID: 16417670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved cancer pain treatment using combined fentanyl-TTS and tramadol.
    Marinangeli F; Ciccozzi A; Aloisio L; Colangeli A; Paladini A; Bajocco C; Coaccioli S; Varrassi G
    Pain Pract; 2007 Dec; 7(4):307-12. PubMed ID: 17986161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel animal model for motion sickness and its first application in rodents.
    Yu XH; Cai GJ; Liu AJ; Chu ZX; Su DF
    Physiol Behav; 2007 Nov; 92(4):702-7. PubMed ID: 17612582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cinnarizine in the prevention of seasickness.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    Aviat Space Environ Med; 1994 Jul; 65(7):606-9. PubMed ID: 7945126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of motion sickness remedies in severe sea conditions.
    Gahlinger PM
    Wilderness Environ Med; 2000; 11(2):136-7. PubMed ID: 10921365
    [No Abstract]   [Full Text] [Related]  

  • 30. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects.
    Ahmed S; Sileno AP; deMeireles JC; Dua R; Pimplaskar HK; Xia WJ; Marinaro J; Langenback E; Matos FJ; Putcha L; Romeo VD; Behl CR
    Pharm Res; 2000 Aug; 17(8):974-7. PubMed ID: 11028944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of simulator sickness in an AH-64 aviator.
    Kroll JD
    Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and application of a radioreceptor assay for scopolamine.
    Ensing K; in 't Hout WG; Halma P; Klinkers HM; Ensing GJ; de Zeeuw RA
    Arzneimittelforschung; 1988 Jan; 38(1):106-11. PubMed ID: 3365270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
    Gan TJ; Sinha AC; Kovac AL; Jones RK; Cohen SA; Battikha JP; Deutsch JS; Pergolizzi JV; ; Glass PS
    Anesth Analg; 2009 May; 108(5):1498-504. PubMed ID: 19372328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR; Gonen A; Nachum Z; Doweck I; Spitzer O; Shupak A
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.